Overview

Silymarin in COVID-19 Pneumonia

Status:
Recruiting

Trial end date:
2021-02-28

Target enrollment:

Participant gender:

Summary

A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, anti-inflammatory and anti-oxidant effects

Phase:

Phase 3

Details

Lead Sponsor:

Cairo University

Treatments:

Silymarin